Biomarkers predicting Alzheimer's disease in cognitively normal aging - PubMed (original) (raw)

Biomarkers predicting Alzheimer's disease in cognitively normal aging

Yong S Shim et al. J Clin Neurol. 2011 Jun.

Abstract

The pathophysiologic process of Alzheimer's disease (AD) begins years before the diagnosis of clinical dementia. This concept of preclinical AD has arisen from the observation of AD pathologic findings such as senile plaques and neurofibrillary tangles in the brains of people who at the time of death had normal cognitive function. Recent advances in biomarker studies now provide the ability to detect the pathologic changes of AD, which are antecedent to symptoms of the illness, in cognitively normal individuals. Functional and structural brain alterations that begin with amyloid-β accumulation already show the patterns of abnormality seen in individuals with dementia due to AD. The presence of preclinical AD provides a critical opportunity for potential interventions with disease-modifying therapy. This review focuses on the studies of antecedent biomarkers for preclinical AD.

Keywords: Alzheimer's disease; biomarker; preclinical.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflicts of interest.

Figures

Fig. 1

Hypothetical cascade of pathophysiology and related biomarkers in Alzheimer's disease (AD). APP: amyloid precursor protein, CSF: cerebrospinal fluid, Aβ: amyloid beta, SP: senile plaque, NFT: neurofibrillary tangle, PIB: pittsburg compound B, p-tau: phosphorylated tau, FDG: fluorodeoxyglucose, PET: positron-emission tomography, MRI: magnetic resonance imaging.

Similar articles

• Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.
  Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM. Berg L, et al. Arch Neurol. 1998 Mar;55(3):326-35. doi: 10.1001/archneur.55.3.326. Arch Neurol. 1998. PMID: 9520006
• NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
  Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. Jack CR Jr, et al. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Alzheimers Dement. 2018. PMID: 29653606 Free PMC article. Review.
• Alzheimer's disease.
  De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. De-Paula VJ, et al. Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
• Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
  Burnham SC, Coloma PM, Li QX, Collins S, Savage G, Laws S, Doecke J, Maruff P, Martins RN, Ames D, Rowe CC, Masters CL, Villemagne VL. Burnham SC, et al. J Prev Alzheimers Dis. 2019;6(4):248-255. doi: 10.14283/jpad.2019.25. J Prev Alzheimers Dis. 2019. PMID: 31686097
• Biomarkers, ketone bodies, and the prevention of Alzheimer's disease.
  VanItallie TB. VanItallie TB. Metabolism. 2015 Mar;64(3 Suppl 1):S51-7. doi: 10.1016/j.metabol.2014.10.033. Epub 2014 Oct 30. Metabolism. 2015. PMID: 25468143 Review.

Cited by

• Age-related alteration in cerebral blood flow and energy failure is correlated with cognitive impairment in the senescence-accelerated prone mouse strain 8 (SAMP8).
  Zhang X, Li G, Guo L, Nie K, Jia Y, Zhao L, Yu J. Zhang X, et al. Neurol Sci. 2013 Nov;34(11):1917-24. doi: 10.1007/s10072-013-1407-8. Epub 2013 Apr 7. Neurol Sci. 2013. PMID: 23563860
• Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction.
  Schicktanz S, Schweda M, Ballenger JF, Fox PJ, Halpern J, Kramer JH, Micco G, Post SG, Thompson C, Knight RT, Jagust WJ. Schicktanz S, et al. Front Hum Neurosci. 2014 Nov 20;8:921. doi: 10.3389/fnhum.2014.00921. eCollection 2014. Front Hum Neurosci. 2014. PMID: 25477802 Free PMC article.
• Morphological and Microstructural Changes of the Hippocampus in Early MCI: A Study Utilizing the Alzheimer's Disease Neuroimaging Initiative Database.
  Lee P, Ryoo H, Park J, Jeong Y; Alzheimer's Disease Neuroimaging Initiative. Lee P, et al. J Clin Neurol. 2017 Apr;13(2):144-154. doi: 10.3988/jcn.2017.13.2.144. Epub 2017 Jan 25. J Clin Neurol. 2017. PMID: 28176504 Free PMC article.
• Observational Study of Clinical and Functional Progression Based on Initial Brain MRI Characteristics in Patients with Alzheimer's Disease.
  Choi H, Yang Y, Han HJ, Jeong JH, Park MY, Kim YB, Jo KD, Choi JY, Kang KH, Kang H, Kwon DY, Yoo BG, Lee HJ, Shin BS, Jeon SM, Kwon OD, Kim JS, Lee SJ, Kim Y, Park TH, Kim YJ, Yang HJ, Park HY, Shin HE, Lee JS, Jung YH, Lee AY, Shin DI, Shin KJ, Park KH. Choi H, et al. J Alzheimers Dis. 2018;66(4):1721-1730. doi: 10.3233/JAD-180565. J Alzheimers Dis. 2018. PMID: 30452413 Free PMC article.
• White matter hypointensities and hyperintensities have equivalent correlations with age and CSF β-amyloid in the nondemented elderly.
  Wei K, Tran T, Chu K, Borzage MT, Braskie MN, Harrington MG, King KS. Wei K, et al. Brain Behav. 2019 Dec;9(12):e01457. doi: 10.1002/brb3.1457. Epub 2019 Nov 6. Brain Behav. 2019. PMID: 31692294 Free PMC article.

References

1. 1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259. - PubMed
2. 1. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985;42:1097–1105. - PubMed
3. 1. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479–486. - PubMed
4. 1. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095–1097. - PubMed
5. 1. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45:358–368. - PubMed

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Korean Neurological Association
  • PubMed Central